The global clinical trial software market, valued at USD 1,017 million in 2025, is projected to reach USD 1,157 million in 2026 and USD 3,685 million by 2035, representing a CAGR of 13.7% during the forecast period. At present, several companies are engaged in the development of clinical trials software, clinical trial management system and CTMS systems, which allow drug developers to enhance the quality of their clinical products and reduce the time to get a product to market. The market has wi...

The non-crispr genome editing therapy market is estimated to be worth $451 million in 2022 and is expected to grow at CAGR of 18% during the forecast period. Isolation of the first site-specific restriction enzyme, Hind II, in the 1970s, became one of the breakthrough advances in biotechnology. In fact, there have been several advancements in the field of genome editing, which provide investigators the ability to introduce sequence-specific modifications into the genomes of a broad spectrum of c...

The myeloid cell targeting therapeutics market is estimated to be worth $652 million in 2022 and is expected to grow at CAGR of over 40% during the forecast period. With several programs having entered the clinical stages, myeloid cells targeting therapeutics have emerged as a novel strategy in the suite of cancer immunotherapy approaches. Over time, many research studies have shown that myeloid cells can interact with the immune system and aid in generating an appropriate anti-tumor immune resp...

The global NGS kits market, valued at USD 2.1 billion in 2025, is projected to reach USD 2.5 billion in 2026 and USD 11.5 billion by 2035, with a 18.3% CAGR during the forecast period 2026 to 2035. Given the ongoing innovation in NGS testing kit and next generation sequencing kits market, stakeholders further believe that, over the next decade, the aforementioned cost may further get reduced to USD 100. It is worth mentioning that this decrease in genome sequencing cost has led to an increase...

Targeted therapeutics is fast emerging as the key focus area in biopharmaceutical industry. Oral targeted therapeutics has attracted many drug developers due to the ease of administration it offers to patients (especially pediatric and geriatric patients). In the case of leukemia, current marketed oral drugs include Gleevec, Tasigna, Sprycel, Bosulif, Imbruvica and Iclusig.

The metal and lipid nanoparticle manufacturing market (service) is estimated to be worth $2.1 billion in 2021 and is expected to grow at compounded annual growth rate (CAGR) of 8.6% during the forecast period. A recent study published in the journal of Analytical and Pharmaceutical Research has highlighted that around 90% of the candidates in the current preclinical development pipeline and more than 40% of the marketed pharmacological products are associated with concerns related to solubility...

The thermostable vaccines market is estimated to be worth $XX billion in 2021 and is expected to grow at compounded annual growth rate (CAGR) of 40% during the forecast period. In some countries, about 80% of the drugs are estimated to lose their potency due to inadequate temperature control during their cold chain transportation. Over time, technological advancements in the methods of biologics development and manufacturing have prompted the developers to explore the potential of thermostable...

Telehealth refers to the remote delivery of healthcare services, such as medical consults, examination / interpretation of medical reports, critical health parameter monitoring, medical information sharing (between physicians and their patients) and patient education, using modern telecommunications solutions. In other words, telehealth services offer a convenient and cost-effective way for individuals with health problems to seek medical attention from the comfort of their respective homes.

The global bioassay services market is estimated to grow from $509 million in 2025 to reach $672 million in 2026 and $1,654 million by 2030, representing a higher CAGR of 25.2% during the forecast period. Given the various advantages of cell and gene therapies and their ability to address the underlying causes of serious clinical conditions, the preference for such therapeutic modalities has increased over the years. As a result, several cell and gene therapies have been developed and approved f...

The “Cushing’s Syndrome: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Cushing’s Syndrome.

The report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Familial Amyloid Polyneuropathy.

The report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Chronic Inflammatory Demyelinating

The report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of X-linked Hypophosphatemia.

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product’s mechanism of action, dosage and administration, and pharmacological studies, regulatory milestones, and other development activities.

The “Hidradenitis Suppurativa: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Hidradenitis Suppurativa.

The “C3 Glomerulopathy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of C3 Glomerulopathy.

The report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Refractory Gout.